Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management

Martina Ledergerber¹, Brian M. Lang², Henriette Heinrich¹, Luc Biedermann¹, Stefan Begré⁴, Jonas Zeitz¹,⁵, Niklas Krupka⁶, Andreas Rickenbacher⁷, Matthias Turina⁷, Thomas Greuter¹, Philipp Schreiner¹, René Roth¹, Alexander Siebenhüner⁸, Stephan R. Vavricka¹, Gerhard Rogler¹, Niko Beerenwinkel²,³ and Benjamin Misselwitz¹,⁶* on behalf of the Swiss IBD Cohort Study Group

**Abstract**

**Background:** Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imitating irritable bowel syndrome (IBS). Several single-nucleotide polymorphisms (SNPs) have been associated with IBS. However, the impact of IBS genetics on the clinical course of IBD, especially pain levels of patients remains unclear.

**Methods:** Data of 857 UC and 1206 CD patients from the Swiss IBD Cohort Study were analysed. We tested the association of the maximum of the abdominal pain item of disease activity indices in UC and CD over the study period with 16 IBS-associated SNPs, using multivariate ANOVA models.

**Results:** In UC patients, the SNPs rs1042713 (located on the ADRB2 gene) and rs4663866 (close to the HES6 gene) were associated with higher abdominal pain levels (P = 0.044; P = 0.037, respectively). Abdominal pain was not associated with any markers of patient management in a model adjusted for confounders. In CD patients, higher levels of abdominal pain correlated with the number of physician contacts (P < 10⁻¹⁵), examinations (P < 10⁻¹²), medical therapies (P = 0.023) and weeks of hospitalisation (P = 0.0013) in a multivariate model.

**Conclusions:** We detected an association between maximal abdominal pain in UC patients and two IBS-associated SNPs. Abdominal pain levels had a pronounced impact on diagnostic and therapeutic procedures in CD but not in UC patients.

**Keywords:** Single-nucleotide polymorphisms, Abdominal pain, Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Irritable bowel syndrome
severe and life-threatening disease or complications [1]. Identification of reliable predictors for the clinical course of IBD would strongly improve patient management.

Genetic predisposition plays a prominent role in IBD pathogenesis. Genome-wide association studies (GWAS) identified more than 240 single-nucleotide polymorphisms (SNPs) associated with the risk for IBD [2–4]. However, in an extensive analysis, even the combined genetic information was largely unable to predict the clinical course of IBD [5]. Therefore, it remains unclear which genetic markers determine patient symptoms, need for therapy and outcome.

Pain is a frequent problem in IBD, affecting approximately 70% of patients and it remains a long-standing problem for every second patient [6]. It is most frequently located in the abdomen and associated with a reduced quality of life (QoL) [7]. The severity of abdominal pain is an integral marker of many scales rating IBD disease activity, including the modified Truelove and Witts disease activity index (MTWAII) for UC [8] and the Crohn's disease activity index (CDAI) [9] or PRO-2 [10] for CD. Abdominal pain is most severe when acute intestinal inflammation is present but many IBD patients with endoscopic remission continue to experience abdominal pain [6, 11].

Abdominal pain in the absence of active inflammation is also characteristic for irritable bowel syndrome (IBS). IBS is a functional gastrointestinal disorder (FGID) and defined by the Rome IV criteria as recurrent abdominal pain at least once a week over the last three months and two or more of the following criteria: relation to defecation, association with changes in stool frequency or changes in stool form [12]. In a meta-analysis, IBS-like symptoms were reported by almost 40% of IBD patients in remission [13], compared to 20% in the general population [14, 15].

Several SNPs have been analysed in the context of IBS in large GWAS and meta-analyses [16–20]. The role of these “IBS-SNPs” in IBS pathogenesis has not yet been fully understood. Since abdominal pain is the leading symptom in IBS, genetic mechanisms contributing to abdominal pain in IBS might also be relevant for levels of abdominal pain in IBD patients. A potential role of IBS-SNPs on the level of pain in patients with IBD has not yet been investigated.

Even though IBD and IBS are fundamentally different conditions, some pathways of pathogenesis including alterations in gut permeability, microbiota, inflammation, enteric nervous system, gut brain axis and psychological factors are partially shared [21]. Moreover, stimulators for abdominal pain such as tension and strong contractions in the gut, cytokines and an increased sensitivity towards visceral stimuli are likely relevant in both conditions [21–26]. It is therefore reasonable to assume, that IBS-associated genetic polymorphisms will also be relevant in IBD. Since pain remains the clinical hallmark of IBS, we hypothesize that IBS-associated polymorphisms will impact on the level of pain in IBD.

In the Swiss IBD cohort study (SIBDC) extensive clinical information and genetic information are available. The primary aim of this study is to test for a possible association of IBS-SNPs and the level of abdominal pain in patients with IBD. The second goal is to explore the effects of abdominal pain on the disease management.

Methods

Patients

The SIBDC has been collecting longitudinal data of IBD patients from all parts of Switzerland since 2006. Patients are followed up yearly, using both a physician and a patient questionnaire. The design and goals of the SIBDC have been described elsewhere [27].

DNA genotyping and selection of SNPs

In 2015, in a comprehensive effort, the genotype of 379 SNPs was determined in all SIBDC patients consenting to genetic analysis provided sufficient biomaterial was available. Selected SNPs comprise genetic markers associated with IBD risk, smoking, primary sclerosing cholangitis, anxiety, depression and pain after a thorough literature search. Genotyping of the SIBDC-SNPs was performed by Matrix-Assisted Laser Desorption/Ionisation–Time of Flight Mass Spectrometry (MALDI-TOF–MS) based SNP genotyping [28]. The complete list of SNPs available in the SIBDC data base is provided as Additional file 2. Serotonin transporter gene (SERT) polymorphisms (S/S, L/S and L/L) associated with IBS [29, 30] could not be determined by MALDI-TOF–MS for technical reasons.

Our selection of SNPs was based on SNPs previously identified in three GWAS [16–18] and two systematic reviews [19, 20]. To account for the more stringent SNP selection in GWAS, we performed a sensitivity analysis which excluded all SNPs not identified by GWAS. 16 SNPs identified in the above-mentioned five studies were also present in the SIBDC database and were selected for further analysis. No linkage disequilibrium (LD) was detected between the 16 selected SNPs (not shown).

IBD disease characteristics, socio-demographic and psychological measures

Clinical, epidemiological, socio-demographic and psychosocial data were extracted in autumn 2015 from the SIBDC database. Patient characteristics include gender, age at diagnosis, disease duration, time interval between IBD diagnosis and SIBDC enrolment, ethnicity, smoking habits [31], education, marital status, physical activity,
alcohol consumption, initial disease location and extent of disease, family history of IBD and extraintestinal manifestations (EIM). To assess mental health the hospital anxiety and depression scale (HADS) was used.

The primary endpoint of our study was maximal abdominal pain, assessed with the abdominal pain item from the CDAI for CD patients and the MTWAI for UC patients, respectively. Both scores distinguish four levels of abdominal pain intensity: none, mild, moderate and severe. We selected the highest reported pain score (i.e. maximum abdominal pain) over the entire observation period. We favoured maximal abdominal pain since it is probably the measure closest associated with the main interest of our study: pain typical for IBD during a flare. During a flare, contacts to the health system is frequent and the likelihood of an assessment for SIBDC is high. During these episodes, the highest pain levels are expected. Using maximal abdominal therefore maximises the chances to focus the assessment on pain due to acute inflammation. Moreover, maximal abdominal pain has been identified in a previous study as having the strongest impact on quality of life [32].

We also used median abdominal pain (i.e. median of all reported abdominal pain values over time) as a secondary readout in a sensitivity analysis. This measure likely integrates assessments during a flare as well as during remission. During remission, abdominal pain might be absent (in the absence of an inflammatory stimulus) or due to post-inflammatory IBS, which is not the focus of our study. In further sensitivity analyses, we also tested pain ever (moderate or severe vs. none or mild abdominal pain) as outcomes. To assess disease activity, we calculated CDAI for CD and MTWAI for UC, according to SIBDC follow-up questionnaires.

For the number of physician contacts we calculated all visits to the primary care physician, gastroenterologist, hospital ambulatories and other doctors, starting three months before enrolment until data extraction. The overall number of medical examinations (abdominal ultrasound, X-rays, CT-scan, MRI, colonoscopies) was used to characterize the vigour of diagnostic efforts. In an additional analysis, the overall number of medical examinations was adjusted for the number of visits.

As a simple summary measure for medical treatments, we added the number of medical therapies ever used during the observation period in each patient. The following six classes of drugs were considered: (1) oral/local prednisone or budesonide, (2) purine analogues (azathioprine, mercaptopurine), (3) sulfasalazine and oral/local 5-amino salicylic acid, (4) methotrexate, (5) TNF-inhibitors (infliximab, adalimumab, certolizumab) and (6) calcineurin inhibitors (cyclosporine, tacrolimus). No SIBDC patient had received vedolizumab or golimumab at time of data extraction. Additionally, the use of TNF-inhibitors (yes or no) was analysed separately.

To calculate the duration of hospitalisation, all weeks spent hospitalised, from 12 months prior to enrolment until data extraction, were summarized. Endpoints for the quality of life were the inflammatory disease questionnaire (IBDQ) [33, 34] and the Short Form 36 Health Survey (SF-36) [35, 36].

Statistical analysis
Data were imported into the statistical program R version 3.3.3 [37]. To assess the relationship between IBS-associated SNPs and the endpoint of interest we first screened for an association of genotype and endpoint using univariate regression. For the multivariate analysis, we performed step-wise model selection, considering disease characteristics, demographic features and psychosocial factors as predictors. Parameters were systematically eliminated by comparing models using the Akaike information criterion (AIC). AIC is a measure for the goodness-of-fit of a given model that takes model complexity into account with a preference for models with a lower number of parameters. We then included SNPs and covariates in a multivariate analysis of variance (ANOVA) model for prediction of our endpoints of interest. We performed model-based t-tests (contrasts) to assess individual associations between SNPs and endpoints while controlling for covariates. We used Bonferroni and Benjamini–Hochberg correction [38] to correct for multiple testing. A corrected p-value (q) < 0.1 was considered significant.

Results
Study population and genetic information
For our analysis, clinical, epidemiological and genetic data of 2063 individuals with IBD were available. 1206 of those patients were diagnosed with CD and 857 with UC. Table 1 provides an overview of the study population; our study population comprises patients with mild, moderate and severe disease. The collected data of up to nine years of follow-up was analysed.

Selection of IBS-associated SNPs
In the SIBDC data base, data relating to 379 SNPs are available (Additional file 2). IBS genetics has been assessed in three GWAS and two meta-analysis [16–20]. Of all SNPs identified in these studies, 16 SNPs associated with IBS were also present in the SIBDC data base (Table 2).
We tested the 16 IBS-associated SNPs (Table 2) for effects on our primary endpoint maximal abdominal pain. In a univariate analysis (Additional file 1: Table S1), rs4663866 (close to the HES6 gene) was strongly associated with maximal abdominal pain in UC patients ($P=0.005$). This association remained significant ($q<0.1$).

**Table 1 Basic data and disease characteristics**

|                                | Overall n = 2063 | CD n = 1206 | UC n = 857 |
|--------------------------------|------------------|-------------|------------|
| **Basic epidemiological and sociodemographic characteristics** |                  |             |            |
| Sex: Female; n (%)             | 1007 (48.8)      | 621 (51.5)  | 386 (45.0) |
| Age at diagnosis, median (sd)  | 31.2 (13.6)      | 29.9 (13.5) | 33.0 (13.5) |
| Age at enrolment (years)       | 41.0 (14.7)      | 40.5 (15)   | 41.8 (14.3) |
| Disease duration (years)       | 14.6 (9.9)       | 15.4 (10.5) | 13.4 (9.1) |
| Duration between diagnosis and enrolment (years) | 9.9 (9.5)       | 10.6 (10)   | 8.76 (8.70) |
| Caucasian; n (%)               | 0.8 (0.4)        | 0.8 (0.4)   | 0.8 (0.4)  |
| Higher education; n (%)        | 447 (27.1)       | 237 (25.2)  | 210 (29.7) |
| Swiss citizenship; n (%)       | 1271 (79.9)      | 732 (80.1)  | 539 (79.7) |
| Married; n (%)                 | 779 (48.1)       | 404 (43.8)  | 375 (54.0) |
| Low physical activity (%)      | 652 (40.9)       | 406 (44.8)  | 246 (35.9) |
| Ever smoke; n (%)              | 955 (46.3)       | 698 (57.9)  | 257 (30.0) |
| Alcohol: rarely or never; n (%)| 938 (57.0)       | 559 (59.4)  | 379 (53.7) |
| Alcohol: frequent (once a day); n (%) | 111 (6.7) | 73 (7.8) | 38 (5.4) |
| Family history of CD; n (%)    | 172 (8.9)        | 143 (12.7)  | 29 (3.6)   |
| Family history of UC; n (%)    | 110 (5.7)        | 37 (3.3)    | 73 (9.2)   |
| **Disease characteristics**    |                  |             |            |
| Disease localisation CD        |                  |             |            |
| Upper gastrointestinal tract   | 11 (0.9)         |             |            |
| Ileal                          | 266 (22.1)       |             |            |
| Ileocolonic                    | 572 (47.4)       |             |            |
| Colonic                        | 263 (21.8)       |             |            |
| Disease localisation UC        |                  |             |            |
| Proctitis                      | 134 (15.6)       |             |            |
| Left-sided colitis             | 286 (33.3)       |             |            |
| Pancolitis                     | 355 (41.3)       |             |            |
| Extraintestinal manifestations, any; n (%) | 1181 (57.2) | 738 (61.2) | 443 (51.6) |
| Extraintestinal manifestation: arthritis/arthralgia; n (%) | 984 (47.7) | 636 (52.7) | 348 (40.6) |
| Fistula in CD; n (%)           | 0.4 (0.48)       |             |            |
| Fistula surgery in CD; n (%)   | 321 (26.6)       |             |            |
| Patients with diarrhoea; n (%) | 1378 (66.7)      | 820 (68)    | 558 (65)   |
| Abdominal mass in CD; n (%)    | 507 (42)         |             |            |
| Abdominal tenderness in UC; n (%) | 349 (40.7) |             |            |
| Nightly diarrhoea in UC; n (%) | 296 (34.5)       |             |            |
| Blood in stool in UC; n (%)    | 448 (52.2)       |             |            |
| Stool incontinence in UC; n (%)| 157 (18.3)       |             |            |
| Abdominal mass in CD; n (%)    | 507 (42)         |             |            |
| Abdominal tenderness in UC; n (%) | 349 (40.7) |             |            |
| Nightly diarrhoea in UC; n (%) | 296 (34.5)       |             |            |
| Blood in stool in UC; n (%)    | 448 (52.2)       |             |            |
| Stool incontinence in UC; n (%)| 157 (18.3)       |             |            |

Statistical analysis: t-test, Fisher’s exact test, Chi-squared test

$n$ number, $sd$ standard deviation

**Association of maximal abdominal pain with IBS-associated SNPs**

We tested the 16 IBS-associated SNPs (Table 2) for effects on our primary endpoint maximal abdominal pain. In a univariate analysis (Additional file 1: Table S1), rs4663866 (close to the HES6 gene) was strongly associated with maximal abdominal pain in UC patients ($P=0.005$). This association remained significant ($q<0.1$).
after the false-discovery rate was controlled by the Benjamini–Hochberg procedure ($q < 0.09$, Fig. 1a). The relationship of maximal abdominal pain with rs4663866 genotype CA/CC compared to AA remained significant in a multivariate ANOVA analysis controlling for covariates ($P = 0.037$).

Our analysis also showed a significant univariate association between rs1042713 (ADRB2 gene, allele GG and AG; $P = 0.012$, $q = 0.09$) and the maximal abdominal pain levels in UC patients (Fig. 1b). This association also remained significant in a multivariate ANOVA test ($P = 0.044$). Details of the difference in outcome according to the genotype (contrast in pain level) of rs4663866 and rs1042713 are shown in Table 3.

In a sensitivity analysis, we restricted our analysis to SNPs for which the association with IBS was identified by a GWAS. Since rs1042713 was not identified in a GWAS, such a stringent SNP selection would limit our results to rs4663866.

In additional sensitivity analyses, we also tested the association of median abdominal pain (instead of maximal abdominal pain) and the binary variable pain level (no or mild pain versus moderate or severe pain) with the selected SNPs. This yielded in similar results for

---

**Table 2 Analysed single-nucleotide polymorphisms**

| Name      | A1A2* | Associated gene                                           | Chromosome | Reference |
|-----------|-------|-----------------------------------------------------------|------------|-----------|
| rs1062613 | CT    | S-HT3A (5-hydroxytryptamine receptor 3E)                  | 11         | [20]      |
| rs12702514| CT    | KDELRE2 (ER lumen protein retaining receptor 2)          | 7          | [16]      |
| rs1800795 | GC    | Il6 (Interleukin 6)                                       | 7          | [19, 20]  |
| rs324420  | CA    | FAAH (Fatty acid amidase hydrolase)                       | 1          | [20]      |
| rs4663866 | AC    | HES6 (Hes family bHLH transcription factor 6)             | 2          | [16]      |
| rs1042173 | AC    | SLC64A (Solute carrier family 6)                          | 17         | [20]      |
| rs1042713 | GA    | ADRB2 (Beta-2-adrenergic receptor)                        | 5          | [20]      |
| rs110402  | GA    | CRHR1 (Corticotropin-releasing hormone receptor 1)        | 17         | [20]      |
| rs2020936 | AG    | SLC64A (Solute carrier family 6)                          | 17         | [20]      |
| rs242924  | TG    | CRHR1 (Corticotropin-releasing hormone receptor 1)        | 17         | [20]      |
| rs3779250 | CT    | CRHR1 (Corticotropin-releasing hormone receptor 2)        | 7          | [20]      |
| rs4680    | GA    | COMT (Catechol-O-methyltransferase)                       | 22         | [20]      |
| rs6269    | AG    | COMT (Catechol-O-methyltransferase)                       | 22         | [20]      |
| rs6311    | CT    | HTR2A (5-hydroxytryptamine receptor 2A)                   | 13         | [20]      |
| rs7432532 | AC    | SCN5A (sodium voltage-gated channel alpha subunit 5)     | 3          | [16]      |
| rs2243250 | CT    | IL4 (Interleukin 4)                                      | 5          | [16, 19, 20] |

* A1: major allele, A2: minor allele

---

**Fig. 1** Impact of IBS-associated SNPs on abdominal pain levels in patients with UC. Pain levels according to allele status of a rs4663866 and b rs1042713. Statistical analysis: univariate linear regression analysis
rs4663866 (median pain: $P = 0.001$, pain level: $P = 0.011$) but showed no significance for rs1042713 (median pain: $P = 0.657$, pain level: $P = 0.089$).

The univariate analysis of the selected SNPs with maximal abdominal pain in patients with CD showed nominal significance for four SNPs (rs1062613, rs3779250, rs4680 and rs6311), which was lost after applying the Benjamini–Hochberg correction ($q > 0.1$) (Additional file 1: Table S1).

### Effects of abdominal pain on disease management in IBD patients

The degree of abdominal pain was strongly associated with the management of IBD patients in a univariate analysis. Patients with severe pain had more clinical visits, more examinations, a higher number of medical therapies and spent more weeks hospitalised (Figs. 2, 3).

In a multivariate analysis controlling for confounders, medical management remained strongly associated with pain in CD (Fig. 4a) but less in UC patients (Fig. 4b). The level of abdominal pain in CD patients was associated with the number of visits during the observation period (incidence rate ratio (IRR) 1.14, $P = 2 \times 10^{-16}$; Additional file 1: Table S2). However, in the UC cohort no such relationship was detectable.

Maximal abdominal pain was also an independent and highly significant predictor for the number of examinations (IRR 1.16, $P = 4.2 \times 10^{-14}$ for UC; IRR 1.29, $P = 1.8 \times 10^{-18}$ for CD; Additional file 1: Table S3). However, other clinical variables including ethnicity, depression and EIM were also associated with the number of examinations. When the number of examinations was adjusted for the number of visits, maximal abdominal pain was no longer a significant predictor in UC patients, whereas in the CD cohort the association remained robust (IRR 1.10, $P = 0.24$ for UC; IRR 1.17, $P = 0.007$ for CD).

In a simplified assessment of the number of medical therapies in IBD patients, we considered six classes of drugs (see methods). For patients with UC and CD, in a univariate analysis, individuals with a higher degree of abdominal pain had been exposed to a higher number of different treatments ($P < 2.0 \times 10^{-16}$ for UC, $P < 2.0 \times 10^{-16}$ for CD, Figs. 2c, 3c). However, in a multivariate analysis, maximal pain remained an independent predictor for the number of therapies only in CD (IRR 1.06, $P = 0.023$; Additional file 1: Table S4), but not in UC. In a sub-analysis, maximal abdominal pain showed a significant association with the use of TNF-inhibitors only in CD patients (odds ratio, OR 1.29, $P = 0.012$), but not in UC patients (data not shown).

Finally, after controlling for confounders maximal pain remained a predictor for hospitalisation weeks only in CD (IRR 1.12, $P = 0.001$; Additional file 1: Table S5), but not in UC.

### IBS-associated SNPs do not influence disease course or management of IBD patients

When IBS-associated SNPs were tested as predictors for clinical endpoints including disease activity, number of visits, examinations, hospitalisation weeks, medical therapies and TNF-inhibitor usage, no significant association robust to Bonferroni or Benjamini–Hochberg correction could be identified (data not shown).

### Discussion

We used data of 2063 patients from the Swiss IBD cohort study to analyse pain in IBD patients. The risk alleles of two IBS-associated SNPs increased maximal pain intensity experienced by UC but not CD patients. IBD patients frequently experience abdominal pain; however, in UC patients pain did not significantly influence management of IBD after controlling for confounders. In contrast, in CD patients, pain was associated with a higher number of physician contacts, examinations, medical therapies and hospitalisation weeks in a multivariate analysis. Both IBS-associated SNPs did not influence patient management.

Pain in IBD might be caused by inflammatory and non-inflammatory pathways. The genetic risk for IBD is mediated by a number of genetic regions [2–4]. However, symptoms of IBD might also be shaped by additional genetic regions associated with IBS, since some pathways of the pathogenesis of both conditions are shared [21–26]. Our analysis suggests for a role of rs4663866 and rs1042713 in mediating the level of pain experienced by IBD patients. Of note, our study does not distinguish between pain due to inflammatory and non-inflammatory conditions. Future studies need to demonstrate whether these genetic polymorphisms affect patient

---

**Table 3 Significant single-nucleotide polymorphisms**

| SNP          | Outcome                        | Contrast | Slope estimate | Lower 95% CI | Upper 95% CI | $P$-value |
|--------------|--------------------------------|----------|----------------|--------------|--------------|-----------|
| rs4663866 (AA – CA/CC) | Maximal abdominal pain | $-0.17$  | $0.082$       | $-0.33$     | $-0.010$     | $0.037$  |
| rs1042713 (AA – AG—GG) | Maximal abdominal pain | $-0.18$  | $0.088$       | $0.35$      | $-0.005$     | $0.044$  |

Difference in outcome according to respective genotype and outcome. Reading example: our model predicts that patients with AA status at the rs4663866 loci have, on average, 0.17 lower maximal abdominal pain than those patients with CA/CC status at the rs4663866 loci. Statistical analysis: model-based t-test (contrasts)
perception of inflammatory pain and/or patient predisposition to develop post-inflammatory IBS (IBD-IBS).

SNP rs1042713 is located on the ADRB2 gene which encodes the beta-2-adrenergic receptor. This receptor plays an important role in pain signalling cascades [39, 40] and polymorphisms in rs1042713 affected agonist-induced receptor downregulation in vitro [41]. Rs1042713 has been associated with pain, consultations and hospitalisations in sickle cell disease [42, 43], temporomandibular pain [44], fibromyalgia [45] and chronic widespread pain [46].

The second SNP associated with abdominal pain, rs4663866, was identified in a GWAS for IBS [16], rs4663866 was associated with the risk for IBS with
nominal but not genome-wide significance ($P = 5 \times 10^{-6}$). SNP rs4663866 is located near the transcription factor HES6 gene but no studies addressing rs4663866 function could be found in literature and mechanistic aspects remain unclear.

We would like to emphasise that testing for post-inflammatory IBS in our study has not been possible for two reasons: First, Rome IV criteria for our patients were not available, preventing a formal diagnosis of IBS in our IBD cohort. Second, the inflammatory state (level of inflammation) has not been rigorously tested in our patients at the time of pain assessment.

In our study, abdominal pain was a crucial predictor for the intensity of disease management in CD patients. Maximal abdominal pain was strongly associated with the number of visits and investigations, TNF-inhibitor

**Fig. 3** Effect of abdominal pain on disease management in patients with CD. Impact of pain on (a) number of visits, (b) number of examinations (ultrasound, endoscopy, X-ray, MRI, CT-scan), (c) cumulative number of drug classes prescribed and (d) number of weeks spent in hospital. Statistical analysis: univariate linear regression analysis.
usage and overall medical therapies as well as the length of time spent hospitalised. In other studies, patient management has also been associated with measures different from acute bowel inflammation. In a longitudinal study, IBS like symptoms in IBD increased the number of clinical visits and examinations during a follow up period of more than 2 years [47]. Furthermore, a recent large cross-sectional study reported an association between IBS-like symptoms and the use of narcotics, clinical visits and the use of some medication after controlling for a limited number of confounders [48].

In our study, pain influenced clinical management in CD but only to a much lower degree in UC. A potential explanation could be the easier clinical assessment of disease activity in UC patients. The rectum is uniformly affected in UC and disease activity directly correlates with the number of bowel movements and bloody diarrhoea. The partial Mayo score (consisting of stool frequency, frequency of bloody stools and physician's global assessment) is an accepted and validated endpoint in clinical studies of UC [49]. Of note, none of the considered IBS-SNPs were associated with IBD management. Therefore, physicians seem to rely on non-ambiguous signs of intestinal inflammation for decisions and genetic changes mediating pain levels might not significantly influence the clinical management.

In contrast, in CD, assessment of disease activity is complex and inflammation especially in the small intestine will not necessarily result in non-ambiguous symptoms, requiring usage of "softer" parameters such as the intensity of abdominal pain for treatment decisions.

Besides pain, our study also identified well-known predictors of severe disease contributing to more intense disease management. EIM were uniformly associated with all endpoints of disease management in both, UC and CD. While abdominal pain was the single symptom most consistently associated with disease management in CD, in UC, the severity of diarrhoea predicted intense management better. Other clinical markers of disease activity such as bloody diarrhoea, abdominal mass and incontinence influenced some but not all outcomes.

Our study has several strengths and limitations. To the best of our knowledge, this study is the first to analyse the association between abdominal pain, SNPs previously analysed in the context of IBS and management and disease course in IBD patients. Due to the extensive data of our cohort, we were able to test and control for many possible epidemiological, sociodemographic and clinical confounders. Limitations include lack of testing for Rome IV criteria (see above). Also, the number of IBS-related SNPs tested in the Swiss IBD cohort is limited and not all SNPs identified by GWAS and systematic reviews were available. If selection of SNPs would be limited to SNPs with an association to IBS identified by a GWAS, only rs4663866 would remain. For instance, none of the SNPs tested were associated with pain in CD and it is possible that pain in CD is mediated by other SNPs. Our study should therefore be considered as pilot study and additional analyses with more SNPs are warranted. Further, effects of rs1042713 and rs4663866 should be confirmed in an independent cohort. No validated pain questionnaires (such as the McGill Pain Questionnaire [50]) could be used because these scores had not been collected in the SIBDC. A questionnaire dedicated to the experience of pain had been used only once in the SIBDC [6] and was filled only by a subset of patients. Therefore, we preferred
to use the pain items in the CDAI and the MTWAI which were repeatedly acquired. The individual perception of pain is based on complex physical mechanisms depending on various psychosocial parameters [51] and ultimately remains a highly subjective experience of an individual. Taking this into account, the pain items of the CDAI and the MTWAI might only partially reflect the level of abdominal pain experienced by patients as they are filled out by physicians, based on patient’s reports.

Conclusions

Our study shows an association between pain levels in UC patients and IBS-associated SNPs, providing genetic evidence for an overlap of some disease mechanisms in IBD and IBS. We did not find an significant association between abdominal pain and patient management in patients with UC. However, in CD patients, pain was a strong predictor for intense patient management with regard to clinical visits, investigations and medical therapies, indicating that physicians use pain levels as a surrogate for disease activity in CD.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01622-x.

Acknowledgements

The authors would like to thank the patients and the staff of the Swiss IBD cohort study for their commitment. The authors would like to thank the patients and the staff of the Swiss IBD cohort study for their commitment. The authors would like to thank the patients and the staff of the Swiss IBD cohort study for their commitment. The authors would like to thank the patients and the staff of the Swiss IBD cohort study for their commitment.

Consent for publication

Not applicable.

Funding

This work was supported by a grant from the Swiss National Science Foundation (SNF) to the Swiss IBD Cohort (Grant No. 3347CO-108792). Funding enabled data acquisition and the genetic analysis of the SIBDC. The analysis at hand was performed by the authors without external funding. The funder did not influence the analysis or interpretation of data and did not influence our decision for publication.

Availability of data and materials

The data that support the findings of this study are available from the SIBDC but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are how ever available from the authors upon reasonable request and with permission from the SIBDC.

Ethics approval and consent to participate

SIBDC has been approved on the 5th of February 2007 by the Cantonal Ethics Committee of the Canton Zürich, Switzerland (EK-1316). At enrolment, participants provided written informed consent. This sub-study was approved by the SIBDC scientific committee (Project No. 2015-19).

Consent for publication

Not applicable.

Competing interests

Martina Ledengerber, Brian M. Lang, Henriette Heinrich, Niklas Koupka, Stefan Begrel, Andreas Rickenbaecher, Matthias Turina and Niko Beerwinkel have no competing interests to declare. Luc Biedermann reports grants from the Swiss National Science Foundation, during the conduct of the study, travel grants from Abbvie, MSD, Vifor, personal fees for consulting and advisory board work from Abbvie, Ferring, MSD, Pfizer, Shire, Takeda, UCB, Janssen and a research grant from ThermostR, outside the submitted work. Jonas Zetz received a research grant from Abbvie and has received travel expenses and registration fees for educational events and conferences from Abbvie, Vifor and Almirall, all outside of the submitted work. Thomas Greuter has received travel reimbursements from Vifor and Falk Pharma, personal fees from Sanofi Aventis
and a grant from the Novartis Foundation, all for work performed outside the current study. Philipp Schreiner reports travel reimbursements from Vifor, from Pfzer and from UBC, all for work performed outside the submitted work. René Roth reports a personal fee from AbbVie AG, outside the submitted work. Alexander R. Schlaefer has served as an advisory board, received consulting honoraria from AMGEN, BMS, JPSLEN, Lilly, Merck, Pfizer, Sanofi and Server for work performed outside the current study. Stephan van Nuck has consulted to/received speaker’s honoraria from: AbbVie, FALK, Ferring, MSD, Novartis, Pfzer, UCB, Takeda, Tillotts, and Vifor, outside the submitted work. Gerhard Rogler has consulted to AbbVie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfzer, Phadia, Roche, UCB, Takeda, Tillotts, Vifor, Vital Solutions and Zeller. Gerhard Rogler has received speaker’s honoraria from Astra Zeneca, AbbVie, FALK, Janssens, MSD, Pfzer, Phadia, Takeda, Tillotts, UCB, Vifor and Zeller; Gerhard Rogler has received educational grants and research grants from AbbVie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfzer, Roche, Takeda, Tillotts, UCB and Zeller; for work performed outside the current study. Benjamin Misselwitz has served at an advisory board for Gilead and Novogenix, has received traveling fees or speaking fees from given Imaging, MSD, Vifor, Takeda and Novartis and has received an unrestricted research grant from MSD, outside of the submitted work.

Author details
1 Department of Gastroenterology, University Hospital Zurich (USZ), Zurich University, Zurich, Switzerland. 2 Department of Biosystems Science and Engineering, ETH Basel, Basel, Switzerland. 3 SB Swiss Institute of Bioinformatics, Basel, Switzerland. 4 Department of Biomedical Research, Neurology, Inselspital and University Clinic of Bern, Bern, Switzerland. 5 Center of Gastroenterology, Clinic Hirlanden, Zurich, Switzerland. 6 Department of Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland. 7 Department of Oncology, Center of Hematology and Oncology University Hospital Zurich (USZ), Zurich University, Zurich, Switzerland.

Received: 20 October 2019   Accepted: 20 January 2021
Published online: 05 February 2021

References
1. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE. 2017;12(10):e0185193.
2. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256–61.
3. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25.
4. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility factor for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE. 2017;12(10):e0185193.
5. Zeitz J, Ak M, Muller-Mottet S, Scharl S, Biedermann L, Fournier N, et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS ONE. 2016;11(6):e0156666.
6. Schirbel A, Reichert A, Roll S, Baumgart DC, Buning C, Witting B, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16(25):3168–77.
7. Trueove SC, Witting LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2(4848):375–8.
8. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. Nat Cooper Crohn’s Dis Study Gastroenterol. 1976;70(3):439–44.
9. Khanna R, Zhou G, D’Haens G, Feagan BG, Sandborn WJ, Vandenoot M, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther. 2015;41(1):77–86.
10. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(5):778–88.
11. Drossman DA. Functional gastrointestinal disorders: What’s new for Rome IV? Lancet Gastroenterol Hepatol. 2016;1(1):6–8.
12. Harlan SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(10):1474–82.
13. Jones R, Lyead S. Irritable bowel syndrome in the general population. BMJ. 1992;304(6819):87–90.
14. Agreus L, Talley NJ, Svardssudd K, Tibblin G, Jones MP. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol. 2000;35(2):142–51.
15. Ek WE, Reznichenko A, Ripke S, Niesler B, Zucchielli M, Rivera NV, et al. Exploring the genetics of irritable bowel syndrome: a GWAS study in the general population and in multicenter national case–control cohorts. Gut. 2015;64(11):1774–82.
16. Holliday EG, Attia J, Hancock S, Koloski N, McEvoy M, Peel R, et al. Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am J Gastroenterol. 2014;109(5):770–2.
17. Bonfiglio F, Henström M, Nag A, Hadizadeh F, Zheng T, Cenit MC, et al. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(e13):e13358.
18. Czogalla B, Schmitteckert S, Houghton LA, Sayuk GS, Camilleri M, Ollivio Diaz A, et al. A meta-analysis of immunogenetic case–control association studies in irritable bowel syndrome. Neurogastroenterol Motil. 2015;27(5):717–27.
19. Zhu S, Wang B, Jia Q, Duan L. Candidate single nucleotide polymorphisms of irritable bowel syndrome: a systemic review and meta-analysis. BMC Gastroenterol. 2019;19(1):165.
20. Szalwinski P, Wlodarczyk J, Spinelli A, Fichna J, Wlodarczyk M. IBS-symp-toms in IBD patients: manifestation of comorbid or different entities. J Clin Med. 2020;10:1.
21. Uno Y. Hypothesis: mechanism of irritable bowel syndrome in inflammatory bowel disease. Med Hypotheses. 2019;132:109324.
22. Salmah M, Meleime L, Moustafa M, do Rejo JC, do Rejo JL, Legrand R, et al. Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. Am J Physiol Gastrointest Liver Physiol. 2019;316(6):G692-G700.
23. Srinath A, Young E, Szegathy E. Pain management in patients with inflammato-ry bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis. 2014;20(12):2433–49.
24. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients’ description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol. 1998;10(5):415–21.
25. Spiller R, Major G. IBS and IBD—separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13(10):613–21.
26. Petrit V, Juillert P, Mottet C, Felley C, Laballeen P, Burnand B, et al. Cohort profile: the Swiss IBD Cohort Study (SBDCS). Int J Epidemiol. 2009;38(4):922–31.
27. Lang BM, Biedermann L, van Haafken WT, de Vallerie C, Schuurmans M, Begre S, et al. Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn’s disease. Aliment Pharmacol Ther. 2018;47(1):55–66.
28. Park JM, Choi MK, Park JA, OH JH, Cho KY, Lee IS, et al. Serotonin transmitter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 2006;18(11):1995–1000.
29. Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol. 2002;97(7):1780–4.
30. Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, et al. High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation data from the Swiss IBD Cohort Study. J Crohns Colitis. 2013;7(10):819–29.
31. Cain KC, Headstrom P, Jarrett ME, Motzer SA, Park H, Burr RL, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(11):124–32.
32. Alrubaiy L, Rikaby I, Dodds P, Hutchings HA, Williams JG. Systematic review of health-related quality of life measures for inflammatory bowel disease. J Crohns Colitis. 2015;9(3):284–92.
34. Janke KH, Steder-Neukamm U, Bauer M, Raible A, Meisner C, Hoffmann JC, et al. Quality of life assessment in Inflammatory Bowel Disease (IBD): German version of the Inflammatory Bowel Disease Questionnaire (IBDQ-D; disease-specific instrument for quality of life assessment)—first application and comparison with international investigations. Gesundheitswesen. 2005;67(8–9):656–64.

35. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med. 1995;41(10):1359–66.

36. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

37. Team RC. R: A language and environment for statistical computing. 2016 [R Foundation for Statistical Computing, Vienna, Austria]. Available from: https://www.R-project.org/.

38. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.

39. Tchivileva IE, Lim PE, Smith SB, Slade GD, Diatchenko L, McLean SA, et al. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics. 2010;20(4):239–48.

40. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maxner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain. 2007;128(3):199–208.

41. Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, et al. Very important pharmacogene summary ADRB2. Pharmacogenet Genomics. 2010;20(1):64–9.

42. Jhun EH, Sadhu N, Hu X, Yao Y, He Y, Wilkie DJ, et al. Beta2-adrenergic receptor polymorphisms and haplotypes associate with chronic pain in sickle cell disease. Front Pharmacol. 2019;10:84.

43. Wonkam A, Mnika K, Ngo Bitoungui VJ, Chetcha Chemegni B, Chimusa ER, Dandara C, et al. Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon. Br J Haematol. 2018;180(1):134–46.

44. Bonato LL, Quinelato V, de Felipe Cordeiro PC, Vieira AR, Granjeiro JM, Tech R, et al. Polymorphisms in COMT, ADRB2 and HTRA1 genes are associated with temporomandibular disorders in individuals with other arthralgias. Cranio. 2019;1–11.

45. Xiao Y, He W, Russell LJ. Genetic polymorphisms of the beta2-adrenergic receptor relate to guanosine protein-coupled stimulator receptor dysfunction in fibromyalgia syndrome. J Rheumatol. 2011;38(6):1095–103.

46. Hocking LJ, Smith BH, Jones GT, Reid DM, Statchan DP, Macfarlane GJ. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain. 2010;149(1):143–51.

47. Gracie DJ, Hamlin PJ, Ford AC. Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. Am J Gastroenterol. 2018;113(5):702–12.

48. Abdalla MI, Sandler RS, Kappelman MD, Martin CF, Chen W, Anton K, et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis. 2017;23(2):325–31.

49. Schroeder KW, Tremaine WJ, Illstrup DM. Coated oral S-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1982;317(26):1625–9.

50. Main CJ. Pain assessment in context: a state of the science review of the McGill pain questionnaire 40 years on. Pain. 2016;157(7):1387–99.

51. Melzack R, Katz J. Pain. Wiley Interdiscip Rev Cogn Sci. 2013;4(1):1–15.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.